05.04.2013 - Austrian and German researchers have presented a blood test to track prostate cancer development.
The new method offers huge benefits to patients who have to be monitored for prostate cancer recurrence by providing a less invasive approach than the currently used biopsies. Instead, study chiefs Jochen Geigl and Michael Speicher from Medical University of Graz and the University Medical Center Hamburg Eppendorf, took blood samples, isolated the patient’s DNA and analysed it using an Illumina benchtop sequencer.
Genomic signatures displayed abnormal copy numbers of specific genetic markers, which indicated resistance against hormone deprivation therapy, the most common form of treatment in men with metastatic prostate cancer. Although being a small scale study including only 25 patients the presence of prostate cancer was flagged by copy number mistakes in sequences such as NCOA2, PHLPP1 and TMPRSS2-ERG. As expected each person's cancer signature was slightly different, however patients whose cancer did not respond to castration all had increased copy numbers of genes for the androgen receptor (AR).
According to the researchers, "the simplicity and low cost of such liquid biopsies make these genetic tests an attractive alternative to traditional biopsies. Better genetic information resulting from these tests may also help target treatment, especially of castration-resistant prostate cancer and aid personalised therapy in the clinic." Two years ago, Swiss researchers had presented a blood test detecting protein biomarkers to track prostate cancer. However, Next-Generation Sequencing is much faster and cheaper.
28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.
20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck.
13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.
09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.